The terminal elimination half-life of Xarelto (rivaroxaban) is 5 to 9 hours in healthy subjects aged 20 to 45 years. The terminal elimination half-life is 11 to 13 hours in the elderly.
Concomitant use of other drugs that impair hemostasis increases the risk of bleeding. These include aspirin, P2Y12 platelet inhibitors, other antithrombotic agents, fibrinolytic therapy, and non-steroidal anti-inflammatory drugs (NSAIDs).
Concomitant use of drugs that are combined P-gp and CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, lopinavir/ritonavir, ritonavir, indinavir, and conivaptan) increases rivaroxaban exposure and may increase bleeding risk.
Avoid concomitant use of XARELTO with drugs that are combined P-gp and strong CYP3A4 inducers (e.g., carbamazepine, phenytoin, rifampin, St. John’s wort).
- Xarelto Information for Consumers
- Xarelto Information for Healthcare Professionals (includes dosage details)
- Side Effects of Xarelto (detailed)
Search for questions
Still looking for answers? Try searching for what you seek or ask your own question.
Posted 9 Feb 2010 • 2 answers
Posted 23 Jan 2012 • 1 answer
Posted 16 Jan 2015 • 1 answer
Posted 9 Feb 2016 • 1 answerFAQ by Drugs.com
Posted 23 Jun 2018 • 0 answers